Filing Flows › Heron Therapeutics (HRTX) › Q4 2024
Heron Therapeutics (HRTX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 27, 2025
Heron Therapeutics (HRTX) reported revenue of $40.8M for the fourth quarter 2024 (Q4 2024), +19% from a year earlier and +24% from the quarter before. Operating margin was 10.2%, net earnings $3.7M (9.0% of revenue).
Heron Therapeutics, Q4 2024: revenue $40.8M (+19% year over year), operating margin 10.2%, net earnings $3.7M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $40.8M | +24% | +19% |
| Gross profit | $30.6M | +31% | +25% |
| Operating profit | $4.2M | — | — |
| Net earnings | $3.7M | — | — |
| Operating cash flow | −$11.8M | — | — |
What changed
Revenue was $40.8M in Q4 2024, up 19% year over year and up 24% from the previous quarter. CINVANTI was the largest line at 66% of revenue.
Gross margin was 74.9%, up 3.8 points from a year earlier. Operating profit was $4.2M, a 10.2% margin (up 40.1 points year over year). Operating expenses fell 24% while revenue rose 19%. Net earnings were $3.7M. The effective tax rate was 0.0%.
Operating cash flow was −$11.8M. Non-cash charges added back $581K of depreciation and amortization and $2.3M of share-based compensation. Working capital and other items used $18.3M. Capital expenditures of $638K exceeded it, leaving free cash flow of −$12.4M.
Questions
What was Heron Therapeutics' revenue in the fourth quarter 2024?
Heron Therapeutics (HRTX) reported revenue of $40.8M for the fourth quarter 2024 (Q4 2024), +19% from a year earlier and +24% from the quarter before.
Was Heron Therapeutics profitable in the fourth quarter 2024?
Operating profit was $4.2M (10.2% of revenue) and net earnings $3.7M.
Source: Heron Therapeutics 10-K on SEC EDGAR.